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of the underlying risk factors (abdominal obesity, physical inactivity, and atherogenic diet). Moreover, hypertensives also require a tight BP control, a choice of antihypertensive treatment not producing other metabolic disturbances, and, quite often, parallel drug treatment for associated metabolic risk factors (dyslipidemia, insulin resistance, and prothrombotic and proinflammatory states).
Lifestyle Interventions
Lifestyle interventions are the first step in achieving cardiometabolic risk reduction. The key lifestyle interventions are the promotion of exercise and energy expenditure and the reduction of overweight by caloric restriction. 19 The minimal requirements for long-term effectiveness include caloric restriction in the range of 500-1,000kcal with 7-10% weight loss in 12 months and regular aerobic exercise of 30-45 minutes daily. Whereas extreme caloric-restricted or element-dissociated diets have no long-term advantages, more intensive exercise programs have additional CV benefits and help to maintain weight loss. Lifestyle interventions have beneficial effects on BP and the lipid profile and reduce the incidence of new-onset diabetes. 20 Moreover, recent data suggest a long-term effect on the reduction in CV morbidity. 21 Other lifestyle changes also have a beneficial effect on specific CV risk factors and must be encouraged in specific patients. Lowering salt intake and alcohol consumption have moderate BP-lowering effects, which are enhanced in conjunction with weight loss and increased exercise. 7 In addition, a diet rich in fruit, vegetables, and low-fat dairy products-dietary approaches to stop hypertension (DASH) diet-substantially lowers BP in comparison with the standard American diet. 22 Finally, the Mediterranean diet, which is also rich in fruit, vegetables, fish, and olive oil, has a favorable impact on atherogenic dyslipidemia in metabolic syndrome patients. 23 Maintenance of lifestyle changes requires counseling and may prove difficult in the long term. For this reason, pharmacological treatment of BP, dyslipidemia, insulin resistance, and obesity will be required for most patients to reduce cardiometabolic risk.
Antihypertensive Therapy
As mentioned above, the new ESH/ESC guidelines 7 antihypertensive therapy is mandatory. 7 For the remaining subjects, there is no consensus on whether antihypertensive treatment is recommendable when lifestyle measures are not effective.
Various evidence can help to guide this decision. First, the Framingham Study 24 found that subjects with high-normal BP were at increased risk for CV events compared with those with optimal BP (less than 120/80mmHg). Second, the rate of developing hypertension in a short period (three years) for those with BP higher than 120/80mmHg has been reported as very high (40% in subjects older than 64 with BP higher than 130/85mmHg). 25 In the same way, the recent Trial of Preventing 
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On the basis of these considerations, it can be hypothesized that antihypertensive treatment could be of benefit for subjects with highnormal BP and high cardiometabolic risk. However, a clear indication needs to be based on a prospective interventional study showing decreased mortality and/or morbidity.
Lipid-lowering Therapy
For hypertensives with cardiometabolic risk but without diabetes or CV disease, the evidence is scarce. However, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) demonstrated that treatment with 10mg atorvastatin was effective in reducing CV events when hypertension was accompanied by three or more additional risk factors, including most that are contained in the definition of metabolic syndrome. 29 The typical dyslipidamia in hypertensives with cardiometabolic risk is characterized by low HDL-cholesterol and increased triglycerides. 
Insulin Sensitizers
In addition to lifestyle changes, treatment with metformin, 20 acarbose, 35 and thiazolidindiones 36 decreases the risk of new-onset diabetes in patients with impaired glucose tolerance. However, the long-term benefits of these drugs and the cost-benefit analysis have not been adequately addressed. In fact, a recent meta-analysis suggests a deleterious effect of rosiglitazone on cardiac outcomes.
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Antiobesity Drugs
Abdominal obesity is one the main components of cardiometabolic risk.
In addition to a restricted caloric diet and increased exercise, three different pharmacological approaches are available for weight loss.
Sibutramine is the only drug affecting monoaminergic systems currently approved for the long-term control of obesity. Several clinical trials have demonstrated the superiority of sibutramine with respect to placebo in reducing weight and waist circumference (median at one year: 4.5kg). In hypertensives, sibutramine slightly increases BP and heart rate and should be used with caution. 38 However, a recent trial suggests that the effects of sibutramine in hypertensives under antihypertensive treatment largely depend on the type of antihypertensive drug used. 39 Thus, sibutraminewhen co-administered with a combination of RAS blockers and calcium channel blockers-does not interfere with the antihypertensive effect of such a combination.
Orlistat is an inhibitor of gastrointestinal lipases, especially pancreatic lipase.
Its efficacy in producing a superior weight loss with respect to placebo has also been proven, although the weight loss is usually less than that obtained with sibutramine. Orlistat has a favorable influence on lipids and glycemic control, especially in diabetics, although gastrointestinal tolerance is poor. 40 Rimonabant is the first antagonist of the endocannabinoid (CB1)
receptor. The Rimonabant In Obesity (RIO) program has demonstrated a significant effect of this drug on long-term weight reduction in overweight patients with additional CV risk factors at one year, 41 maintained at two years, 42 in hyperlipidemic overweight subjects, 43 and in type 2 diabetics. 44 In all these trials, the beneficial effects on HDLcholesterol and triglycerides, and on glycated hemoglobin in diabetics, exceeded those expected due to weight loss.
These facts have led to the consideration that Rimonabant is a drug primarily directed to CV protection through a direct reduction of the components of cardiometabolic risk. Studies of the effect of this CB1
receptor antagonist on CV outcomes in patients at risk are ongoing.
Antithrombotic Drugs
A key feature of metabolic syndrome that explains the increased cardiometabolic risk is an enhanced pro-thrombotic state, especially in the presence of insulin resistance. Postprandial hyperglycemia, increased free fatty acids, and elevated triglyceride levels may all have adverse effects on platelets, coagulation, and fibrinolysis. Pharmacological interventions targeting these abnormalities have the potential to reduce thrombosis.
Antiplatelet drugs such as low-dose aspirin or clopidogrel represent an option in the management of hypertensives with cardiometabolic risk. The benefit is probably higher in type 2 diabetics 45 and conclusive in those with previous CV disease. 46 Efforts to control BP should be reinforced before the introduction of aspirin.
Anti-inflammatory Drugs
Insulin resistance is now recognized as an inflammatory disease, with levels of inflammatory markers such as C-reactive protein, plasminogen activator inhibitor (PAI)-1, and interleukin (IL)-6 being present in higher concentrations in insulin-resistant individuals than in healthy counterparts. 47 C-reactive protein is increasingly regarded as a useful measure of CV risk. 48 Aspirin, statins, and-to a lesser extent-RAS inhibitors reduce the 
Closing Remarks
Although there are several areas of uncertainty with respect to the definition, usefulness, and pathogenesis of metabolic syndrome, simple clinical tools exist that identify subjects at a higher risk of developing both type 2 diabetes and CV disease, and thus having high cardiometabolic risk. The management of these subjects is based principally on lifestyle measures, but various antihypertensive, lipidlowering, insulin-sensitizing, antiobesity, and antiplatelet drugs could be helpful in reducing the cardiometabolic risk.
Population-based strategies are necessary to reduce the impact of underlying risk factors for cardiometabolic risk (obesity, physical inactivity, and atherogenic diet). Although evidence is scarce, there is general agreement that more aggressive therapy is required to reduce the risk of new diabetes and CV disease further. Prospective, randomized trials addressing the effect of potentially beneficial treatments on cardiometabolic outcomes should be strongly encouraged. ■
